Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

'Bhuvan should be accessed by different organisations'
Bhuvan, an indigenously developed satellite mapping tool similar to Google Earth, should be widely accessed by different organisations and agencies for their programmes, Science and Technology Minister Prithviraj Chavan said today.

India Inc resumes hiring drive amid recovery signals
In a major relief for jobseekers, India Inc"s hiring activities are picking up once again as economic conditions are looking up considerably, experts say.

News of the day

Sun gets support of RMG in battle against Taro
Sun Pharmaceutical Industries’ attempts to take over Israeli drug major Taro Pharmaceutical is gaining more support from independent advisory firms. RiskMetrics Group’s ISS Governance Services (RMG), an independent proxy advisory firm, has recommended that shareholders of Taro Pharmaceutical Industries vote against all the proposals made by Taro’s board of directors, including all of its nominees for election and re-election as directors in the upcoming Annual General Meeting (AGM) scheduled for December 31, Sun Pharma said in a press release.
Business Ideas

Glenmark Pharma Q2 net dips 31% to Rs 81 cr

Drug maker Glenmark Pharmaceuticals today reported 31 per cent drop in its consolidated net profit at Rs 80.88 crore for the second quarter ended September 2009. - Aurobindo gets SA regulator"s nod to market drugs - Glenmark Generics files IPO prospectus with Sebi - Glenmark raises Rs 413 cr in QIP - Natco to make 10 mn strips of generic Tamiflu available by Oct - Glenmark plans to raise Rs 300-350 cr through QIP - Glenmark"s drug fails clinical trials Total income rose to Rs 616.56 crore during the quarter from Rs 604.21 crore against the year-ago period, Glenmark said in a filing to the Bombay Stock Exchange (BSE). "Sales growth across most regions for the quarter has improved. The India formulations business and the US generics business performed well during the quarter," Glenmark Pharma CEO & MD Glenn Saldanha said. The company"s sales from formulations business in India increased 18 per cent to Rs 184.26 crore, while the revenue from the US generics business rose to Rs 177.11 crore from Rs 176.13 crore in the same period last fiscal. "For the remaining part of the year, we expect demand conditions to further improve across all our operating regions. While the US Generics and the India formulations business should continue to grow, the remaining regions are also expected to register good growth rates," Saldanha added. During the period, Glenmark"s revenue from Africa, Asia and CIS (Commonwealth of Independent States) grew 14 per cent to Rs 80.22 crore. On a stand alone basis, Glenmark Pharma posted a net profit of Rs 57.50 crore for the September quarter, a 14.03 per cent drop over the year-ago period. Shares of Glenmark Pharma were trading at Rs 220, down 0.18 per cent over previous close on the BSE.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009